Biomimetic material degradation for synergistic enhanced therapy by regulating endogenous energy metabolism imaging under hypothermia

Kai Cheng, Bo Liu, Xiao-Shuai Zhang, Ruo-Yun Zhang, Fang Zhang, Ghazal Ashraf, Guo-Qing Fan, Ming-Yu Tian, Xing Sun, Jing Yuan () and Yuan-Di Zhao ()
Additional contact information
Kai Cheng: Huazhong University of Science and Technology
Bo Liu: Huazhong University of Science and Technology
Xiao-Shuai Zhang: Huazhong University of Science and Technology
Ruo-Yun Zhang: Huazhong University of Science and Technology
Fang Zhang: Huazhong University of Science and Technology
Ghazal Ashraf: Huazhong University of Science and Technology
Guo-Qing Fan: Huazhong University of Science and Technology
Ming-Yu Tian: Huazhong University of Science and Technology
Xing Sun: Huazhong University of Science and Technology
Jing Yuan: Huazhong University of Science and Technology
Yuan-Di Zhao: Huazhong University of Science and Technology

Nature Communications, 2022, vol. 13, issue 1, 1-18

Abstract: Abstract Inefficient tumour treatment approaches often cause fatal tumour metastases. Here, we report a biomimetic multifunctional nanoplatform explicitly engineered with a Co-based metal organic framework polydopamine heterostructure (MOF-PDA), anethole trithione (ADT), and a macrophage membrane. Co-MOF degradation in the tumour microenvironment releases Co2+, which results in the downregulation of HSP90 expression and the inhibition of cellular heat resistance, thereby improving the photothermal therapy effect of PDA. H2S secretion after the enzymatic hydrolysis of ADT leads to high-concentration gas therapy. Moreover, ADT changes the balance between nicotinamide adenine dinucleotide/flavin adenine dinucleotide (NADH/FAD) during tumour glycolysis. ATP synthesis is limited by NADH consumption, which triggers a certain degree of tumour growth inhibition and results in starvation therapy. Potentiated 2D/3D autofluorescence imaging of NADH/FAD is also achieved in liquid nitrogen and employed to efficiently monitor tumour therapy. The developed biomimetic nanoplatform provides an approach to treat orthotopic tumours and inhibit metastasis.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32349-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32349-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32349-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().